Genmab is a Danish biotechnology firm that develops antibody-based treatments for cancer and other conditions. The company markets several approved therapies including EPKINLY and TEPKINLY for certain lymphomas, Tivdak for cervical cancer, and co-marketed products like DARZALEX for multiple myeloma and RYBREVANT for lung cancer, while maintaining a pipeline of experimental candidates targeting various solid and blood-based malignancies as well as non-oncology indications. Genmab collaborates with major pharmaceutical and biotech partners including AbbVie, Pfizer, Johnson & Johnson, and others.

entry readiness 0 · NOT READY · exit proximity 80

Value area 23.62–38.16 · 12% of 120d volume overhead · clean runway